We present our findings in the following categories: the normal role of CDKN2A/B and effect of their deletion in translational studies; identification of CDKN2A/B deletions; CDKN2A/B deletions in clinical studies; management of tumours with CDKN2A/B homozygous deletions; and putting CDKN2A/B deletions in perspective. The gene discussed is CDKN2A; the disease is neoplasm.